Greater Noida, India
Greater Noida, India

Time filter

Source Type

Point and interval hypothesis tests performed to validate two simple and economical, kinetic spectrophotometric methods for the assay of lansoprazole are described. The methods are based on the formation of chelate complex of the drug with Fe(III) and Zn(II). The reaction is followed spectrophotometrically by measuring the rate of change of absorbance of coloured chelates of the drug with Fe(III) and Zn(II) at 445 and 510 nm, respectively. The stoichiometric ratio of lansoprazole to Fe(III) and Zn(II) complexes were found to be 1 : 1 and 2 : 1, respectively. The initial-rate and fixed-time methods are adopted for determination of drug concentrations. The calibration graphs are linear in the range 50-200 μgml -1 (initial-rate method), 20-180 μgml -1 (fixed-time method) for lansoprazole-Fe(III) complex and 120-300 (initial-rate method), and 90-210 μgml -1 (fixed-time method) for lansoprazole-Zn(II) complex. The inter-day and intra-day precision data showed good accuracy and precision of the proposed procedure for analysis of lansoprazole. The point and interval hypothesis tests indicate that the proposed procedures are not biased. Copyright © 2010 John Wiley & Sons, Ltd.


Singh J.,Amrapali Institute of Technology and science | Shukla S.K.,Jubilant Organosys Ltd. | Shaik B.,National Institute of Technical Teachers Training and Research | Agrawal V.K.,National Institute of Technical Teachers Training and Research
Oxidation Communications | Year: 2013

Modelling of calcium channel antagonists activity of 1,4-dihydropyridine (DHP) derivatives (41 compounds) was carried out using topological descriptors. A 6-parametric model containing Jhetm, Jhetp, 1χ , 0χv, 2χv and Sz as correlating parameters was found to be the best. The model was tested using cross-validation method.


Kamble R.R.,Karnatak University | Biradar D.B.,Jubilant Organosys Ltd. | Meti G.Y.,Karnatak University | Taj T.,Karnatak University | And 6 more authors.
Journal of Chemical Sciences | Year: 2011

Derivatives of 1,3-thiazolidin-2,4-dione appended to biphenyl ring viz., 7-9, 16-18 were prepared. The newly synthesized compounds were confirmed by IR, NMR (1H and 13(C) MS and elemental analyses. Single crystal X-ray diffraction study was carried out for one of the final compounds 9. © Indian Academy of Sciences.


Ali J.,Jamia Hamdard University | Ali J.,Jubilant Organosys Ltd | Saigal N.,Jamia Hamdard University | Saigal N.,Jubilant Organosys Ltd | And 6 more authors.
Recent Patents on Drug Delivery and Formulation | Year: 2010

Pulsatile drug delivery system capable of releasing the drug after a predetermined lag period in pulsed or controlled release manner recently has drawn the attention of both academic and industrial research. Depending on the effective therapeutic application of the drug, a variety of design strategies have been formulated in the pursuit of pulsatile release. Circadian (24 hr cycle) dependency of various physiological and pathological functions is well established, thus, it becomes imperative to develop a drug delivery system to achieve release of drug at specific site and time. Such systems are advantageous for drugs which have an extensive first pass metabolism, biological tolerance, needs targeting of locally absorbed /active drug to a specific site in intestine and are useful for the therapy for chronopharmacological needs. This manuscript portrays the important patents related to chronomodulated release system such as system with eroding, rupturing or soluble barrier coatings. In addition, recently developed chronotherapeutic dosage forms including tablets, capsules, pellets, beads implants, osmotic pump, liposome, thermoresponsive, inflammation stimuli sensitive, electrical stimuli sensitive, ultrasound stimuli responsive, magnetic stimuli responsive etc. are also conferred. © 2010 Bentham Science Publishers Ltd.


Reddy G.V.R.,Jubilant Organosys Ltd | Reddy B.V.,Jubilant Organosys Ltd | Haque S.W.,Jubilant Organosys Ltd | Gautam H.D.,Jubilant Organosys Ltd | And 3 more authors.
Quimica Nova | Year: 2011

The present work describes a novel stability-indicating reversed-phase ultra performance liquid chromatography method for the separation and quantification of rosuvastatin (RSV) and its related impurities in the pharmaceutical dosage forms under forced degradation conditions. An unknown degradation impurity detected in the acid degradation was identified by using quadrupole time-of-flight mass spectrometry. The chromatographic separation was carried out on C-18 column (100 × 2.1 mm, 1.7 μm) using isocratic elution with methanol and 0.1% trifluoroacetic acid (50:50). The total run time was 12 min within which RSV as well as all related impurities and degradation products were separated. The developed method was validated for RSV and related impurities in pharmaceutical dosage forms.


Dubey S.K.,Jubilant Organosys Ltd | Kharbanda M.,Jubilant Organosys Ltd | Mathela C.S.,Kumaun University
Chemical and Pharmaceutical Bulletin | Year: 2010

An economical new process has been developed for the synthesis of donepezil hydrochloride (1) an anti-Alzheimer's drug. The process involves Darzen reaction of pyridine-4-carboxaldehyde and 2-bromo-5,6-dimethoxy indanone affording epoxide 5,6-dimethoxy-3-(pyridine-4-yl)spiro[indene-2,2′-oxiran] -1(3H)-one (4) as a key intermediate. The one-pot deoxygenation of 4 and hydrogenation of the aryl moiety in high yield improved the overall yield of the process. © 2010 Pharmaceutical Society of Japan.


Mishra S.,Indian Institute of Technology Delhi | Singh J.,Jubilant Organosys Ltd | Choudhary V.,Indian Institute of Technology Delhi
Journal of Applied Polymer Science | Year: 2010

The butyl acrylate (BA)/methyl methacrylate (MMA), and glycidyl methacrylate (GMA) composite copolymer latex was synthesized by seeded emulsion polymerization technique taking poly(methyl methacrylate) (PMMA) latex as the seed. Four series of experiments were carried out by varying the ratio of BA : MMA (w/w) (i.e. 3.1 : 1, 2.3 : 1, 1.8 : 1, and 1.5 : 1) and in each series GMA content was varied from 1 to 5% (w/w). The structural properties of the copolymer were analyzed by FTIR, 1H-, and 13C-NMR. Morphological characterization was carried out using transmission electron microscopy (TEM). In all the experiments, monomer conversion was ̃99% and final copolymer composition was similar to that of feed composition. The incorporation of GMA into the copolymer chain was confirmed by 13C-NMR. The glass transition temperature (T g) of the copolymer latex obtained from the differential scanning calorimetry (DSC) curve was comparable to the values calculated theoretically. With increase in GMA content, particles having core-shell morphology were obtained, and there was a decrease in the particle size as we go from 2-5% (w/w) of GMA. The adhesive strength of the latexes was found to be dependent on the monomer composition. With increase in BA : MMA ratio, the tackiness of the film increased while with its decrease the hardness of the film increased. © 2009 Wiley Periodicals, Inc.


Disclosed herein is a process for large scale production of pure 4-(4-halo-1-oxybutyl)-,-dimethylbenzene acetic acid or alkyl esters thereof, wherein the process comprises of condensing (2-halo-1,1-dimethyl-ethyl)benzene with acetate salt followed by acylation with -halo compound, hydrolyzing and cyclizing the resultant regioisomers, subsequently oxidizing and purifying to obtain pure regioisomer, further halogenating and/or esterifying the para regioisomer to produce 4-(4-halo-1-oxybutyl)-,-dimethylbenzene acetic acid or their alkyl esters.


Patent
JUBILANT ORGANOSYS Ltd | Date: 2010-08-06

Disclosed herein are novel polymorphic forms of Fluvastatin sodium, wherein said polymorphic forms are designated as J_(F), J_(F1), J_(F2), J_(F3 )and are characterized by their powder X-ray diffraction patterns, Infrared absorption spectrums, thermo gravimetric analysis and differential scanning calorimetry. The processes for preparing said polymorphic forms are also disclosed. The present invention also relates to process for preparing amorphous form of Fluvastatin sodium.


Disclosed is a process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine. The process comprises condensing 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine or a salt thereof with N-methyl piperazine to produce 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, wherein the process is carried out in the absence of a solvent. Also disclosed is a process for obtaining the Polymorphic Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine by crystallizing the crude 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine in a mixture of solvents.

Loading Jubilant Organosys Ltd collaborators
Loading Jubilant Organosys Ltd collaborators